ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
ENDRA Life Sciences Inc. (NDRA), a Delaware corporation, filed this Current Report on Form 8-K on March 31, 2026. The filing serves to announce the Company's financial results for the quarter and full year ended December 31, 2025. The Company's principal executive offices are located in Ann Arbor, Michigan.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K acts as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1.
Material Changes
No material changes or comparative financial data are detailed within the body of this filing. The document references the attached press release for the full disclosure of results for the period ended December 31, 2025.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 31, 2026) for actual financial figures.
- Verify the specific revenue and net income/loss for the quarter and year ended December 31, 2025.
- Check the press release for any updates on the Company's cash position and burn rate.
- Confirm if any new guidance or operational milestones were announced in the attached press release.